EP4019019
Notkun á rílúsól, rílúsól-forlyfjum eða rílúsól-hliðstæðum með ónæmismeðferðum til að meðhöndla krabbamein
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
19.5.2017EP published:
7.2.2024EP application number:
21207246.6
EP translation filed:
6.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
18.5.2037Expiry date:
18.5.2026Next due date:
31.5.2026
Title in English:
USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERSLanguage of the patent:
English
Timeline
Today
19.5.2017EP application
7.2.2024EP Publication
6.5.2024Translation submitted
15.6.2024Registration published
18.5.2026Expires
Owner
Name:
Biohaven Therapeutics Ltd.Address:
215 Church Street, New Haven, CT 06510, US
Inventor
Name:
CORIC, VladimirAddress:
New Haven, 06520, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662339433 PDate:
20.5.2016Country:
US
Classification
Categories:
A61K 31/428, C07D 277/82, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 6.6.2024
Expires: 18.5.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 6.5.2025
Expires: 18.5.2026
Payer: Árnason Faktor ehf.